<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04114032</url>
  </required_header>
  <id_info>
    <org_study_id>EPIC-2:BNP</org_study_id>
    <nct_id>NCT04114032</nct_id>
  </id_info>
  <brief_title>BNP Evaluation Before Surgery Study: an Observational Study of Natriuretic Peptide Levels Prior to Surgery.</brief_title>
  <acronym>EPIC-2</acronym>
  <official_title>Evaluating Perioperative Interventions to Improve Patient outComes (EPIC-2): BNP Evaluation Before Surgery Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cape Town</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multi-centre, observational study of preoperative natriuretic peptide testing&#xD;
      for patients undergoing non-cardiac surgery conducted over four weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Identification of high-risk surgical patients requires risk stratification. Current clinical&#xD;
      risk stratification tools, e.g. Revised Cardiac Risk Index (RCRI), only have a moderate&#xD;
      ability to identify these patients. International guidelines, like Canadian Cardiovascular&#xD;
      Society on perioperative cardiovascular risk assessment, advocate that all patients 45 yrs&#xD;
      and older or patients &gt;18y rs who have significant cardiovascular disease and who are coming&#xD;
      for intermediate to high-risk surgery, should get natriuretic peptide (NP) testing. This is&#xD;
      because raised preoperative B-type natriuretic peptides have a strong association with&#xD;
      postoperative cardiac complications according to observational studies and meta-analyses.&#xD;
&#xD;
      However, in these patients with significant cardiovascular disease coming for intermediate to&#xD;
      high-risk surgery it is unknown how many patients will actually have raised B-type&#xD;
      natriuretic peptides. That is, which group of patients have an even higher risk in this&#xD;
      already high-risk group. Natriuretic peptide (NP) testing is also expensive.&#xD;
&#xD;
      Further identification of patients that need NP testing will reduce costs and focus efforts&#xD;
      on those patients who really need it.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Actual">April 29, 2020</completion_date>
  <primary_completion_date type="Actual">April 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Raised natriuretic peptide</measure>
    <time_frame>preoperative</time_frame>
    <description>Determine the prevalence of abnormal (raised) NP in patients with clinical risk criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk prediction</measure>
    <time_frame>preoperative</time_frame>
    <description>The secondary objective is to develop a risk prediction model for those patients who will need preoperative NP screening.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">174</enrollment>
  <condition>Surgery, Cardiovascular</condition>
  <arm_group>
    <arm_group_label>High-risk elective surgical patients</arm_group_label>
    <description>The patient population to be studied are elective patients for non-cardiac surgery.&#xD;
Age ≥ 45 years of age.&#xD;
Undergoing intermediate or major non-cardiac surgery requiring an overnight stay in hospital.&#xD;
With at least one of the following criteria:&#xD;
History of ischaemic heart disease or peripheral vascular disease (coronary equivalent)&#xD;
History of stroke or transient ischaemic attack&#xD;
History of congestive cardiac failure&#xD;
Diabetes currently on an oral hypoglycaemic agent or insulin&#xD;
Serum creatinine &gt;175 µmol/L (&gt;2.0mg/dl)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population comprises all non-cardiac patients 45yrs presenting for elective&#xD;
        surgery at Groote Schuur-, Somerset-, Paarl-, Victoria-, Mitchell's Plain-, Worcester-, and&#xD;
        George Hospital over a period four weeks.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 45 years of age.&#xD;
&#xD;
          2. Undergoing intermediate or major non-cardiac surgery requiring an overnight stay in&#xD;
             hospital.&#xD;
&#xD;
          3. With at least one of the following criteria:&#xD;
&#xD;
               1. History of ischaemic heart disease or peripheral vascular disease (coronary&#xD;
                  equivalent)&#xD;
&#xD;
               2. History of stroke or transient ischaemic attack&#xD;
&#xD;
               3. History of congestive cardiac failure&#xD;
&#xD;
               4. Diabetes currently on an oral hypoglycaemic agent or insulin&#xD;
&#xD;
               5. Serum creatinine &gt;175 µmol/L (&gt;2.0mg/dl)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient refusal to participate.&#xD;
&#xD;
          2. Patients presenting for cardiac and obstetric or emergency surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Groote Schuur Hospital</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7935</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cape Town</investigator_affiliation>
    <investigator_full_name>Bruce Biccard</investigator_full_name>
    <investigator_title>Second Chair, Department of Anaesthesia and Perioperative Medicine, Professor</investigator_title>
  </responsible_party>
  <keyword>High risk surgical patients</keyword>
  <keyword>Risk stratification</keyword>
  <keyword>Natriuretic peptide testing</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

